ArticleThe oncologist2016

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.

Saad Usmani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.